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Background
The reason to stop the first biologic may vary from agent
to agent and also from the earlier times to the more recent
ones. Issues like the availability of newer alternatives or a
better knowledge of the effectiveness and safety profile of
individual biologics may influence treatment decisions,
including the discontinuation of the biologic.
Objective
To visually assess the relationship between the reason for
stopping the first biologic and the period of time when the
biologic was started.
Methods
All patients with rheumatoid arthritis undergoing treat-
ment with a biologic are registered in the clinical database
of a single center with seven treating rheumatologists. The
biologic used, as well as the reason to stop it is recorded,
as well as all dates regarding the start and the last dose.
We performed a multiple correspondence analysis with
the Burt method of adjusted inertias and standard normal-
ization with the variables: first biologic, time period (1998-
2001, 2002-2005, 2006-2009), and reason to stop (adverse
event, inefficacy, others). Correspondence analysis provides
a means of displaying or summarizing a set of data with
categorical variables in two-dimensional graphical form.
Results
The total inertia of the exploratory analysis was 0.10.
The first two dimensions added to 57% of the inertia, so
that all dimensions were accounted for. The major
drives of the relationship between the three variables
were “infliximab” and the time period “1998-2001”
(% inertia 0.146 and 0.177, respectively). The distance
between other categories of the three variables was not
relevant enough to make any suggestions of an associa-
tion. (See Figure 1).
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Conclusions
Time has affected the decision to start infliximab, with
more treatments started in the earlier times than in the
later ones. The reason to stop any first biologic does not
clearly relate to the time neither to the biologic itself in
this single center dataset.
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